Determination of free fatty acids in human tumors by mass spectrometry with MRM technique

据世界卫生组织报道，近年来，由于环境、职业及饮食结构等因素的改变，慢病(NCD)成为了导致残疾和死亡的重要原因，导致死亡的人数已经达到了死亡总人数的约60%，同时也导致了全球疾病经济负担逐渐加重。因此，NCD已经成为一个全球性的极其重要的公共卫生问题。其中，恶性肿瘤也称癌症，又是目前NCD中导致死亡的最重要原因。因此，控制肿瘤向恶性发展，提高癌症的预防和治疗水平尤为重要。 游离脂肪酸(FFAs)为细胞的主要代谢产物，在组织中FFAs合成的增强是癌症的一个重要特征。因此，组织中FFAs的研究已经成为了一项新的评估肿瘤进展和癌症生物标志物的研究，其含量测定方法的研究也成为了一项有意义的临床诊断及...According to the statistics, the disease and death spectrum change significantly in recent years and NCD have become the leading cause of death. Malignant tumor is a major reason of death for NCD. It has become a major disease which seriously endangers human life and health, and restricts the development of society and economy. The key to the treatment of malignant tumors is three early, including...学位：工程硕士院系专业：化学化工学院_工程硕士(化学工程)学号：X201119200

Observation of inhomogeneous plasmonic field distribution in a nanocavity

等离激元材料和器件中电场的强度分布是等离激元技术及其应用的重要基础。虽然针尖增强光谱成像技术的发展已经实现了亚纳米的横向空间分辨率，并发现了亚纳米级电场的不均匀性，但是迄今人们对电场的纵向场强分布仍然知之甚少。李剑锋教授课题组设计了一种具有~2Å空间分辨率的分子尺，利用金单晶基底和壳层隔绝金纳米粒子来构筑等离激元纳米腔，并通过分子尺的拉曼信号强度，精准地直接表征纳米腔中的纵轴方向上高度不均匀的场强分布。中国科学技术大学罗毅教授课题组利用基于量子场论的局域场光谱理论，精确地模拟得到了与实验相符的等离激元纳腔中的场分布，并发现了因分子自聚焦作用而引起的“等离激元梳”。该工作提供了一种通用有效的定量表征纳腔中场强分布的方法，完善了对等离激元学基础的理解，为超高空间分辨的拉曼光谱成像、光学力调控分子组装、单分子反应操控提供指导。 该工作是在李剑锋教授和中国科学技术大学罗毅教授共同指导下完成的。实验部分主要由李超禹（论文第一作者，已毕业博士）、温宝英（在读博士）、李松波（已毕业硕士）完成，复旦大学段赛研究员（论文共同第一作者）和陈舒（已毕业博士）进行了局域场光谱理论计算。谢立强（已毕业博士）和毛秉伟教授帮助完成了扫描探针显微镜实验。浙江师范大学周小顺教授和王亚浩老师提供了自组装膜表征方面的重要帮助。印度的Kathiresan、叶龙武教授课题组和浙江大学陆展教授课题组在分子合成方面提供了重要帮助。瑞士伯尔尼大学Wandlowski教授和田中群教授为该工作提供了指导。【Abstract】The progress of plasmon-based technologies relies on an understanding of the properties of the enhanced electromagnetic fields generated by the coupling nanostrucutres.Plasmon-enhanced applications include advanced spectroscopies, optomechanics, optomagnetics and biosensing. However, precise determination of plasmon field intensity distribution within a nanogap remains challenging. Here, we demonstrate a molecular ruler made from a set of viologen-based, self-assembly monolayers with which we precisely measures field distribution within a plasmon nanocavity with ~2-Å spatial resolution. We observed an unusually large plasmon field intensity inhomogeneity that we attribute to the formation of a plasmonic comb in the nanocavity. As a consequence, we posit that the generally adopted continuous media approximation for molecular monolayers should be used carefully.The progress of plasmon-based technologies relies on an understanding of the properties of the enhanced electromagnetic fields generated by the coupling nanostrucutres1,2,3,4,5,6. Plasmon-enhanced applications include advanced spectroscopies7,8,9,10, optomechanics11, optomagnetics12 and biosensing13,14,15,16,17. However, precise determination of plasmon field intensity distribution within a nanogap remains challenging. Here, we demonstrate a molecular ruler made from a set of viologen-based, self-assembly monolayers with which we precisely measures field distribution within a plasmon nanocavity with ~2-Å spatial resolution. We observed an unusually large plasmon field intensity inhomogeneity that we attribute to the formation of a plasmonic comb in the nanocavity. As a consequence, we posit that the generally adopted continuous media approximation for molecular monolayers should be used carefully.The Swedish National Infrastructure for Computing is acknowledged for computer time. S.D. is sponsored by Shanghai Pujiang Programme (grant no. 19PJ1400600). 该研究工作得到国家自然科学基金、国家重点研发计划、安徽省量子信息技术引导专项等的资助和支持

Quantitative Determination of Smaditerpenic Acids A and C in Leaves of Smallanthus sonchifolius by HPLC-MS

通信作者：[email protected][中文文摘]建立了同时测定亚贡(Smallanthus sonchifolius)叶中亚贡二萜酸A和C含量的方法.采用高效液相色谱-质谱法,多反应监测(MRM)模式,大黄素为内标,色谱柱:UltimateTM XB-C18(150mm×4.6mm,5μm);流动相:V(甲醇)∶V(0.5%醋酸水溶液)=90∶10;流速:1.0mL/min;柱温:25℃.亚贡二萜酸A和C的线性范围均为0.2～10.0μg/mL(r≥0.999),平均加样回收率(n=6)分别为96.6%和92.4%,相对标准偏差(RSD)分别为1.9%和3.2%.实验数据表明,该方法操作简单、准确,且重复性好,可用于亚贡叶的质量控制.[英文文摘]A new fast and sensitive high-performance liquid chromatography-electrospray ionization tandem mass spectrometry(HPLC-ESI-MS/MS) method was developed and validated for smaditerpenic acids A and C in leaves of Smallanthus sonchifolius using emodin as internal standard(IS).The calibration curves of smaditerpenic acids A and C were investigated with a good linear relationship within the rangs of 0.2-10.0 μg/mL(r≥0.999),and the recoveries(n=6) were 96.6% and 92.4% with RSD of 1.9% and 3.2%,respectively.The analytes were detected in negative ion mode using multiple reaction monitoring(MRM).The method was validated and the specificity,linearity,lower limit of quantitation(LLOQ)precision,accuracy,recoveries and stability were determined.福建省自然科学基金项目(2009J01192);厦门市重大科技计划项目(3502Z20100006

Pipeline type dam

本实用新型涉及堤坝，特别涉及一种管道式堤坝。管道式堤坝通过多个管道首尾相连围合成封闭的蓄水池，管道的下部掩埋在土壤内、且管道通过间隔设置的多个固定组件固定，管道式堤坝的上方间隔设有多个进水口。本实用新型围水不漏、易于拆卸、施工简单及成本低廉。同时，潮水从管道式堤坝上方的开口处进入管道内，增加管道重量，使管道堤坝在潮汐涨落过程中更稳定

Method for comprehensive treatment of alterniflora through terraced-field flooding and mowing

本发明属于生态环境工程技术领域，具体地说是一种梯田式围淹加刈割综合防治互花米草的方法。在互花米草治理区，分别修建垂直于海岸线和平行于海岸线的堤坝，堤坝相互连接，把治理区围封为封闭区域，区域内的互花米草，于其拔节期后期刈割其地上部分，涨潮时堤坝蓄住潮水，对治理区内刈割后的互花米草根茬形成梯田式围淹，至不再萌生新的互花米草，移除堤坝，恢复海滩自然环境。本发明的方法简单易行，堤坝蓄水性能好，适用性强，既适用于小范围米草治理，也适用于大范围米草治理，互花米草治理效果好，成本较低，对环境影响小，易于恢复海滩生态环境

草炭绿化荒漠

1993-1996年与日本草炭研究会开始“草炭绿化荒漠”的研究工作,1997-2000年开始执行中日政府间JICA合作研究,1998年9月-2001年9月开始中国科学院重大国际合作特别支持项目。该项目以中国科学院阜康荒漠生态试验站为基地,利用草炭改良荒漠,寻求绿化荒漠的新方法、新技术,改善干旱区环境为目的。研究包括草炭的基本性质、土壤-植物系统与水份关系、草炭改土效果、草炭制剂的研究制、草炭利用新技术、草炭的土壤中分解速率和利用年限、草炭绿化荒漠机理等。研制的“草炭土壤调理剂”获发明专利,该制剂可为作物提供全方位的水份和养份供应,为有机肥工业化提供了良好前景;研究方法上采用了盆栽、小区和同位素..

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials